Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Elizabeth Appleton
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity
Abstract INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS Acknowledgments Supplementary Materials REFERENCES Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Chimeric antigen receptor (CAR) T cell therapy faces many challenges against solid tumors including T cell exhaustion and poor CAR durability.
Oncolytic viruses as anticancer agents: clinical progress and remaining challenges
Get full text access Log in, subscribe or purchase for full access. References 1. Chesney, JA ∙ Ribas, A ∙ Long, GV ∙ et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma J Clin Oncol. 2023; 41:528-540 2. Hurley, J ∙ Reis, IM ∙ Rodgers, SE ∙ et al.
Oncolytic viruses as anticancer agents: clinical progress and remaining challenges
Get full text access Log in, subscribe or purchase for full access. References 1. Chesney, JA ∙ Ribas, A ∙ Long, GV ∙ et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma J Clin Oncol. 2023; 41:528-540 2. Hurley, J ∙ Reis, IM ∙ Rodgers, SE ∙ et al.
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion - Nature Communications
Correction to: Nature Communications https://doi.org/10.1038/s41467-025-60133-5, published online 25 May 2025 In the version of the article initially published, the surname of Malin Pedersen appeared incorrectly (as Pederson) and has now been amended in the HTML and PDF versions of the article.
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models - Nature Communications
|
Abstract Reovirus type 3 Dearing (RT3D) is an oncolytic, double-stranded RNA virus. To identify potential RT3D drug-viral sensitizer, here we use a high-throughput screen of therapeutic agents and find a PARP-1 inhibitor, talazoparib, as a top hit. RT3D interacts with retinoic acid-induced gene-1 (RIG-I) and activates PARP-1, with consequent PARylation of components of the extrinsic apoptosis pathway.
By Joan N. Kyula-Currie, Victoria Roulstone, James Wright, Francesca Butera, Arnaud J. Legrand, Richard Elliott, Dragomir B. Krastev, Stephen Pettitt, Magnus T. Dillon, Shane Foo, Emmanuel C. Patin, Elizabeth Appleton, Antonio J. Rullán, Jyoti Choudhary, Chris Bakal, Pascal Meier, Christopher Lord Verified, Alan A Melcher
|
Nature
Verified
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion - Nature Communications
Abstract Cytoplasmic pattern recognition receptors (PRR) for double-stranded RNA, such as RIG-I/MDA5, are key mediators of anti-viral responses. Here we screen for synergistic drug-virotherapy combinations and find that the reovirus type III Dearing strain (Rt3D)-palbociclib combination augments oncolytic virus-induced stress responses and increases interferon production and signaling.
IFNB induced by non-lytic virus immunotherapy promotes improved survival in hepatocellular carcinoma, mediated by MHCII-independent cytotoxic CD4+ T-cells
Abstract Hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths worldwide. Combination immunotherapy is now standard of care for advanced HCC, improving patient outcomes. However, a considerable number of patients remain unresponsive, or are unable to tolerate therapy. Tyrosine kinase inhibitors (TKIs), such as the former first-line agent sorafenib, remain an option for such patients, yet provide only marginal efficacy.
TKI-conditioned immunotherapy using uv-inactivated reovirus promotes survival in hepatocellular carcinoma, mediated by cytotoxic CD4+ T-cells
ABSTRACT Hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths worldwide. Whilst immunotherapy combination regimens are now standard of care for advanced HCC, tyrosine kinase inhibitors (TKIs), such as the former first-line agent sorafenib, remain an important choice for those unable to tolerate immunotherapies but provide marginal efficacy.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Elizabeth
Contact Elizabeth, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack